Equities analysts predict that Repligen Co. (NASDAQ:RGEN) will post sales of $41.33 million for the current quarter, according to Zacks. Five analysts have issued estimates for Repligen’s earnings, with the highest sales estimate coming in at $42.06 million and the lowest estimate coming in at $40.90 million. Repligen posted sales of $25.60 million during the same quarter last year, which would indicate a positive year over year growth rate of 61.4%. The business is scheduled to report its next quarterly earnings results before the market opens on Thursday, February 22nd.
On average, analysts expect that Repligen will report full year sales of $41.33 million for the current financial year, with estimates ranging from $140.50 million to $141.68 million. For the next fiscal year, analysts expect that the business will report sales of $184.79 million per share, with estimates ranging from $181.63 million to $190.00 million. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that cover Repligen.
RGEN has been the subject of several analyst reports. CL King initiated coverage on shares of Repligen in a report on Monday, November 13th. They issued a “buy” rating and a $41.00 target price for the company. TheStreet lowered shares of Repligen from a “b-” rating to a “c” rating in a report on Monday, November 13th. JPMorgan Chase & Co. initiated coverage on shares of Repligen in a report on Tuesday, December 5th. They issued an “overweight” rating and a $42.00 target price for the company. Citigroup started coverage on shares of Repligen in a report on Friday, December 8th. They issued a “buy” rating and a $45.00 target price for the company. Finally, BidaskClub upgraded Repligen from a “hold” rating to a “buy” rating in a research note on Saturday, December 30th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $44.38.
Repligen (NASDAQ:RGEN) traded down $0.11 during trading on Tuesday, reaching $32.75. 154,769 shares of the company traded hands, compared to its average volume of 261,681. The stock has a market cap of $1,426.75, a price-to-earnings ratio of 55.51, a price-to-earnings-growth ratio of 1.84 and a beta of 0.91. Repligen has a one year low of $29.56 and a one year high of $46.81.
In other news, VP Howard Benjamin sold 12,729 shares of the stock in a transaction that occurred on Thursday, December 14th. The stock was sold at an average price of $35.34, for a total transaction of $449,842.86. Following the completion of the transaction, the vice president now directly owns 36,554 shares in the company, valued at approximately $1,291,818.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Anthony Hunt sold 8,970 shares of the stock in a transaction that occurred on Monday, January 22nd. The shares were sold at an average price of $35.95, for a total value of $322,471.50. Following the transaction, the chief executive officer now owns 83,613 shares of the company’s stock, valued at $3,005,887.35. The disclosure for this sale can be found here. Corporate insiders own 1.50% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the company. SG Americas Securities LLC bought a new position in shares of Repligen during the 3rd quarter valued at approximately $180,000. PNC Financial Services Group Inc. boosted its position in shares of Repligen by 162.8% during the 2nd quarter. PNC Financial Services Group Inc. now owns 5,635 shares of the biotechnology company’s stock valued at $234,000 after acquiring an additional 3,491 shares during the last quarter. Crossmark Global Holdings Inc. bought a new position in shares of Repligen during the 3rd quarter valued at approximately $241,000. Brown Advisory Inc. bought a new position in shares of Repligen during the 3rd quarter valued at approximately $310,000. Finally, Piedmont Investment Advisors LLC bought a new position in shares of Repligen during the 2nd quarter valued at approximately $331,000. Hedge funds and other institutional investors own 83.48% of the company’s stock.
Repligen Company Profile
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.